Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.23 -3.6%	$4.15	$1.89 ▼ $5.82	$1.26B	0.65	5.07 million shs	2.59 million shs
EVO Evotec	$3.57 -1.9%	$4.00	$2.84 ▼ $5.64	$1.27B	1.67	95,823 shs	33,199 shs
PAHC Phibro Animal Health	$31.94 -1.6%	$28.31	$16.16 ▼ $32.95	$1.29B	0.8	259,379 shs	205,444 shs
TNXP Tonix Pharmaceuticals	$34.59 -8.9%	$41.48	$6.76 ▼ $130.00	$303.35M	1.7	1.40 million shs	914,589 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	-4.36%	-14.09%	+122.84%	+68.20%
EVO Evotec	0.00%	-3.19%	-14.55%	-23.04%	+8.66%
PAHC Phibro Animal Health	0.00%	+5.84%	+11.24%	+39.67%	+55.01%
TNXP Tonix Pharmaceuticals	0.00%	-26.16%	-23.61%	+31.28%	+11.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.064 of 5 stars	3.5	1.0	0.0	0.0	1.8	3.3	0.0
EVO Evotec	1.5247 of 5 stars	3.3	2.0	0.0	0.0	1.6	0.0	0.6
PAHC Phibro Animal Health	3.4317 of 5 stars	0.9	2.0	2.5	1.1	2.0	3.3	2.5
TNXP Tonix Pharmaceuticals	2.9848 of 5 stars	3.5	2.0	0.0	0.0	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	89.13% Upside
EVO Evotec	2.50	Moderate Buy	$5.40	51.26% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-23.61% Downside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	102.37% Upside

Current Analyst Ratings Breakdown

Latest TNXP, ABCL, PAHC, and EVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	EVO Evotec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	43.84	N/A	N/A	$3.58 per share	1.18
EVO Evotec	$862.40M	1.47	N/A	N/A	$2.91 per share	1.23
PAHC Phibro Animal Health	$1.19B	1.09	$2.08 per share	15.36	$6.34 per share	5.04
TNXP Tonix Pharmaceuticals	$10.09M	30.06	N/A	N/A	$31.82 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	11/3/2025 (Estimated)
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-20.14%	-16.94%	-8.14%	11/5/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	40.95	15.21	0.54	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	11/11/2025 (Estimated)

Latest TNXP, ABCL, PAHC, and EVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.50%	N/A	61.54%	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest TNXP, ABCL, PAHC, and EVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
EVO Evotec	0.42	1.58	1.49
PAHC Phibro Animal Health	2.67	2.91	1.23
TNXP Tonix Pharmaceuticals	N/A	7.53	7.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
EVO Evotec	5.81%
PAHC Phibro Animal Health	99.34%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
EVO Evotec	N/A
PAHC Phibro Animal Health	50.07%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
EVO Evotec	4,827	355.11 million	N/A	Not Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable

TNXP, ABCL, PAHC, and EVO Headlines

Recent News About These Companies

Carolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

August 22 at 9:37 AM | insidertrades.com

SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP

August 20, 2025 | msn.com

Tonix Pharma Announces FDA Approval of Tonmya

August 19, 2025 | msn.com

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

August 19, 2025 | seekingalpha.com

Tonix Pharmaceuticals Reports Q2 2025 Financial Results

August 19, 2025 | msn.com

FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide

August 18, 2025 | msn.com

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

August 18, 2025 | finance.yahoo.com

Tonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA Approval

August 18, 2025 | gurufocus.com

FDA Approves New Fibromyalgia Drug, Tonix Shares Climb

August 18, 2025 | msn.com

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

August 18, 2025 | msn.com

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLC

August 18, 2025 | marketbeat.com

Noble Financial Has Pessimistic Outlook of TNXP Q3 Earnings

August 17, 2025 | marketbeat.com

FDA approves first new fibromyalgia treatment in over 15 years

August 16, 2025 | thepharmaletter.comT

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

Tonix Secures Fibromyalgia Approval - What Investors Should Know

August 16, 2025 | seekingalpha.com

Tonix Pharma Gains FDA Approval for Tonmya

August 16, 2025 | msn.com

Noble Financial Has Negative Estimate for TNXP Q3 Earnings

August 16, 2025 | americanbankingnews.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

August 15, 2025 | manilatimes.netM

Tonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of Tonmya

August 15, 2025 | msn.com

Tonix Pharmaceuticals stock halted ahead of FDA approval news

August 15, 2025 | investing.com

Form 8K Tonix Pharmaceuticals Holding Corp For: 15 August

August 15, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ABCL, PAHC, and EVO Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.23 -0.16 (-3.64%)

Closing price 04:00 PM Eastern

Extended Trading

$4.22 -0.01 (-0.12%)

As of 05:36 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Evotec NASDAQ:EVO

$3.57 -0.07 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 -0.01 (-0.28%)

As of 05:25 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Phibro Animal Health NASDAQ:PAHC

$31.94 -0.52 (-1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$31.98 +0.04 (+0.11%)

As of 04:10 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Tonix Pharmaceuticals NASDAQ:TNXP

$34.59 -3.39 (-8.93%)

Closing price 04:00 PM Eastern

Extended Trading

$34.03 -0.56 (-1.62%)

As of 05:36 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time